205 related articles for article (PubMed ID: 27818211)
1. Deep sequencing for HIV-1 clinical management.
Casadellà M; Paredes R
Virus Res; 2017 Jul; 239():69-81. PubMed ID: 27818211
[TBL] [Abstract][Full Text] [Related]
2. Next generation sequencing improves detection of drug resistance mutations in infants after PMTCT failure.
Fisher RG; Smith DM; Murrell B; Slabbert R; Kirby BM; Edson C; Cotton MF; Haubrich RH; Kosakovsky Pond SL; Van Zyl GU
J Clin Virol; 2015 Jan; 62():48-53. PubMed ID: 25542470
[TBL] [Abstract][Full Text] [Related]
3. Limited Marginal Utility of Deep Sequencing for HIV Drug Resistance Testing in the Age of Integrase Inhibitors.
Dalmat RR; Makhsous N; Pepper GG; Magaret A; Jerome KR; Wald A; Greninger AL
J Clin Microbiol; 2018 Dec; 56(12):. PubMed ID: 30305383
[TBL] [Abstract][Full Text] [Related]
4. Comparison of an
Tzou PL; Ariyaratne P; Varghese V; Lee C; Rakhmanaliev E; Villy C; Yee M; Tan K; Michel G; Pinsky BA; Shafer RW
J Clin Microbiol; 2018 Jun; 56(6):. PubMed ID: 29618499
[TBL] [Abstract][Full Text] [Related]
5. External Quality Assessment for Next-Generation Sequencing-Based HIV Drug Resistance Testing: Unique Requirements and Challenges.
Lee ER; Gao F; Sandstrom P; Ji H
Viruses; 2020 May; 12(5):. PubMed ID: 32429382
[TBL] [Abstract][Full Text] [Related]
6. Routine drug resistance testing in HIV-1 proviral DNA, using an automated next- generation sequencing assay.
Alidjinou EK; Coulon P; Hallaert C; Robineau O; Meybeck A; Huleux T; Ajana F; Hober D; Bocket L
J Clin Virol; 2019 Dec; 121():104207. PubMed ID: 31707202
[TBL] [Abstract][Full Text] [Related]
7. HIV-1 genotypic resistance testing using the Vela automated next-generation sequencing platform.
Raymond S; Nicot F; Carcenac R; Lefebvre C; Jeanne N; Saune K; Delobel P; Izopet J
J Antimicrob Chemother; 2018 May; 73(5):1152-1157. PubMed ID: 29444253
[TBL] [Abstract][Full Text] [Related]
8. Promises and pitfalls of Illumina sequencing for HIV resistance genotyping.
Brumme CJ; Poon AFY
Virus Res; 2017 Jul; 239():97-105. PubMed ID: 27993623
[TBL] [Abstract][Full Text] [Related]
9. Next-Generation Sequencing for HIV Drug Resistance Testing: Laboratory, Clinical, and Implementation Considerations.
Ávila-Ríos S; Parkin N; Swanstrom R; Paredes R; Shafer R; Ji H; Kantor R
Viruses; 2020 Jun; 12(6):. PubMed ID: 32516949
[TBL] [Abstract][Full Text] [Related]
10. Evaluation of Automatic Analysis of Ultradeep Pyrosequencing Raw Data to Determine Percentages of HIV Resistance Mutations in Patients Followed-Up in Hospital.
Bellecave P; Recordon-Pinson P; Fleury H
AIDS Res Hum Retroviruses; 2016 Jan; 32(1):85-92. PubMed ID: 26529549
[TBL] [Abstract][Full Text] [Related]
11. MinVar: A rapid and versatile tool for HIV-1 drug resistance genotyping by deep sequencing.
Huber M; Metzner KJ; Geissberger FD; Shah C; Leemann C; Klimkait T; Böni J; Trkola A; Zagordi O
J Virol Methods; 2017 Feb; 240():7-13. PubMed ID: 27867045
[TBL] [Abstract][Full Text] [Related]
12. Technologies for HIV-1 drug resistance testing: inventory and needs.
Metzner KJ
Curr Opin HIV AIDS; 2022 Jul; 17(4):222-228. PubMed ID: 35762377
[TBL] [Abstract][Full Text] [Related]
13. Cost-efficient HIV-1 drug resistance surveillance using multiplexed high-throughput amplicon sequencing: implications for use in low- and middle-income countries.
Ekici H; Rao SD; Sönnerborg A; Ramprasad VL; Gupta R; Neogi U
J Antimicrob Chemother; 2014 Dec; 69(12):3349-55. PubMed ID: 25085657
[TBL] [Abstract][Full Text] [Related]
14. Evaluation of Vela Diagnostics HIV-1 genotyping assay on an automated next generation sequencing platform.
May S; Adamska E; Tang J
J Clin Virol; 2020 Jun; 127():104376. PubMed ID: 32344322
[TBL] [Abstract][Full Text] [Related]
15. The Evolving Landscape of HIV Drug Resistance Diagnostics for Expanding Testing in Resource-Limited Settings.
Inzaule SC; Hamers RL; Paredes R; Yang C; Schuurman R; Rinke de Wit TF
AIDS Rev; 2017; 19(4):219-230. PubMed ID: 28182618
[TBL] [Abstract][Full Text] [Related]
16. Prospective Evaluation of the Vela Diagnostics Next-Generation Sequencing Platform for HIV-1 Genotypic Resistance Testing.
Weber J; Volkova I; Sahoo MK; Tzou PL; Shafer RW; Pinsky BA
J Mol Diagn; 2019 Nov; 21(6):961-970. PubMed ID: 31382033
[TBL] [Abstract][Full Text] [Related]
17. HIV-1 Drug Resistance Genotyping in Resource Limited Settings: Current and Future Perspectives in Sequencing Technologies.
Manyana S; Gounder L; Pillay M; Manasa J; Naidoo K; Chimukangara B
Viruses; 2021 Jun; 13(6):. PubMed ID: 34208165
[TBL] [Abstract][Full Text] [Related]
18. Ultradeep sequencing in the therapeutic management of HIV-1 infection at treatment initiation.
Todesco E; Mercier-Darty M; Jung M; Bottero J; Boyd A; Marcelin AG; Calvez V; Morand-Joubert L
J Antimicrob Chemother; 2015; 70(6):1919-20. PubMed ID: 25637517
[No Abstract] [Full Text] [Related]
19. Analytical Assessment of the Vela Diagnostics NGS Assay for HIV Genotyping and Resistance Testing: The Apulian Experience.
Bonifacio MA; Genchi C; Lagioia A; Talamo V; Volpe A; Mariggiò MA
Int J Mol Sci; 2022 Mar; 23(5):. PubMed ID: 35269868
[TBL] [Abstract][Full Text] [Related]
20. Treatment options after virological failure of first-line tenofovir-based regimens in South Africa: an analysis by deep sequencing.
Casadellà M; Noguera-Julian M; Sunpath H; Gordon M; Rodriguez C; Parera M; Kuritzkes DR; Marconi VC; Paredes R
AIDS; 2016 Apr; 30(7):1137-40. PubMed ID: 26807968
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
